top of page

KEY PUBLICATIONS

  1. Olislagers, M., de Jong, F.C., Rutten, V.C. Boormans, J.L., Mahmoudi, T., Zuiverloon T.C.M. Molecular biomarkers of progression in non-muscle-invasive bladder cancer — beyond conventional risk stratification. Nat Rev Urol (2024).

  2. Rao S, Romal S, Torenvliet B, Slotman J.A , Huijs T, Mahmoudi T, A 3D organoid platform that supports liver-stage P.falciparum infection can be used to identify intrahepatic antimalarial drugs, Heliyon, 2024 May 30, https://doi.org/10.1016/j.heliyon.2024.e30740

  3. Jones RT, Scholtes M, Goodspeed A, Akbarzadeh M, Mohapatra S, Feldman LE, Vekony H, Jean A, Tilton CB, Orman MV, Romal S, Deiter C, Kan TW, Xander N, Araki SP, Joshi M, Javaid M, Clambey ET, Layer R, Laajala TD, Parker SJ, Mahmoudi T, Zuiverloon TCM, Theodorescu D, Costello JC. NPEPPS Is a Druggable Driver of Platinum Resistance. Cancer Res. 2024 Mar 27:OF1-OF20. doi: 10.1158/0008-5472.CAN-23-1976.

  4. Crespo R, Ne E, Reinders J, Meier JIJ, Li C, Jansen S, Górska A, Koçer S, Kan TW, Doff W, Dekkers D, Demmers J, Palstra RJ, Rao S, Mahmoudi T. PCID2 dysregulates transcription and viral RNA processing to promote HIV-1 latency. iScience. 2024 Feb 6;27(3):109152. doi: 10.1016/j.isci.2024.109152.

  5. Hossain T, Lungu C, de Schrijver S, Kuali M, Rao S, Ngubane A, Kan TW, Palstra RJ, Madlala P, Ndung’u T, Mahmoudi T, SQuHIVLa: A novel assay for Specific Quantification of inducible HIV-1 reservoir by LAMP, bioRxiv 2023.07.14.548928; doi: https://doi.org/10.1101/2023.07.14.548928. Pre-print

  6. Lungu C, Hossain T, Prins H.A.B, Hensley K.S, Crespo R, Rokx C, Rao S, Van Kampen J.J.A, Van de Vijver D.A.M.C, Mesplède T, Katsikis P.D, Mueller Y.M, Gruters R.A, Mahmoudi. Analytical treatment interruption: detection of an increase in the latent, inducible HIV-1 reservoir more than a decade after viral resuppression Pre-print MedRxiv, 2023

  7. Meyers NL, Ashuach T, Lyons DE, Khalid MM, Simoneau CR, Erickson AL, Bouhaddou M, Nguyen TT, Kumar GR, Taha TY, Natarajan V, Baron JL, Neff N, Zanini F, Mahmoudi T, Quake SR, Krogan NJ, Cooper S, McDevitt TC, Yosef N, Ott M. Hepatitis C virus infects and perturbs liver stem cells. mBio. 2023 Nov 8;14(6):e0131823. doi: 10.1128/mbio.01318-23. 

  8. de Jong FC, Laajala TD, Hoedemaeker RF, Jordan KR, van der Made ACJ, Boevé ER, van der Schoot DKE, Nieuwkamer B, Janssen EAM, Mahmoudi T, Boormans JL, Theodorescu D, Costello JC, Zuiverloon TCM. Non-muscle-invasive bladder cancer molecular subtypes predict differential response to intravesical Bacillus Calmette-Guérin. Sci Transl Med. 2023 May 24;15(697):eabn4118. doi: 10.1126/scitranslmed.abn4118

  9. Rao S. Sex differences in HIV-1 persistence and the implications for a cure. Front Glob Womens Health. 2022 Sep 23;3:942345. doi: 10.3389/fgwh.2022.942345.

  10. Ne E, Crespo R, Izquierdo-Lara R, Rao S, Koçer S, Górska A, van Staveren T, Kan TW, van de Vijver D, Dekkers D, Rokx C, Moulos P, Hatzis P, Palstra RJ, Demmers J, Mahmoudi T. Catchet-MS identifies IKZF1-targeting thalidomide analogues as novel HIV-1 latency reversal agents. Nucleic Acids Res. 2022 Jun 10;50(10):5577-5598. 

  11. Crespo R, Rao S, Mahmoudi T. HibeRNAtion: HIV-1 RNA Metabolism and Viral Latency. Front Cell Inf Micro. 2022. Jun 14 https://doi.org/10.3389/fcimb.2022.855092

  12. Rao S, Mahmoudi T. DEAD-ly Affairs: The Roles of DEAD-Box Proteins on HIV-1 Viral RNA Metabolism Front Cell Inf Micro. 2022. Jun 13 https://doi.org/10.3389/fcell.2022.917599

  13. Hossain T, Romal S, Mahmoudi T. Production of Recombinant Hepatitis B virus (HBV) and Detection of HBV in Infected Human Liver Organoids. Bio Protoc. 2022;12(8):e4392. Published 2022 Apr 20. doi:10.21769/BioProtoc.4392

  14. Romal S, Hossain T, Mahmoudi T. Generation, Maintenance and HBV Infection of Human Liver Organoids. Bio Protoc. 2022;12(6):e4358. Published 2022 Mar 20. doi:10.21769/BioProtoc.4358

  15. Rao S, Lungu C, Crespo R, Steijaert TH, Gorska A, Palstra RJ, et al. Selective cell death in HIV-1-infected cells by DDX3 inhibitors leads to depletion of the inducible reservoir. Nat Commun. 2021;12(1):2475.

  16. Röling M, Mollapour Sisakht M, Ne E, Moulos P, Crespo R, Stoszko M, De Crignis E, Bodmer H, Kan TW, Akbarzadeh M, Harokopos V, Hatzis P, Palstra RJ, Mahmoudi T. A Two-Color Haploid Genetic Screen Identifies Novel Host Factors Involved in HIV-1 Latency. mBio. 2021 Dec 21;12(6):e0298021. doi: 10.1128/mBio.02980-21

  17. De Crignis E, Hossain T, Romal S, Carofiglio F, Moulos P, Khalid MM, et al. Application of human liver organoids as a patient-derived primary model for HBV infection and related hepatocellular carcinoma. Elife. 2021;10

  18. Stoszko M, Al-Hatmi AMS, Skriba A, Roling M, Ne E, Crespo R, et al. Gliotoxin, identified from a screen of fungal metabolites, disrupts 7SK snRNP, releases P-TEFb, and reverses HIV-1 latency. Sci Adv. 2020;6(33):eaba6617.

  19. Lungu C, Procopio FA, Overmars RJ, Beerkens RJJ, Voermans JJC, Rao S, et al. Inter-Laboratory Reproducibility of Inducible HIV-1 Reservoir Quantification by TILDA. Viruses. 2020;12(9).

  20. Crespo R, Rokx C, Mahmoudi T. Towards the next step: LoViRet patients for HIV-1 cure studies. EBioMedicine. 2020;58:102889.

  21. Bertoldi A, D'Urbano V, Bon I, Verbon A, Rokx C, Boucher C, et al. Development of C-TILDA: A modified TILDA method for reservoir quantification in long term treated patients infected with subtype C HIV-1. J Virol Methods. 2020;276:113778.

  22. Zhao M, De Crignis E, Rokx C, Verbon A, van Gelder T, Mahmoudi T, et al. T cell toxicity of HIV latency reversing agents. Pharmacol Res. 2019;139:524-34.

  23. Stoszko M, Ne E, Abner E, Mahmoudi T. A broad drug arsenal to attack a strenuous latent HIV reservoir. Curr Opin Virol. 2019;38:37-53.

  24. Palstra RJ, de Crignis E, Roling MD, van Staveren T, Kan TW, van Ijcken W, et al. Allele-specific long-distance regulation dictates IL-32 isoform switching and mediates susceptibility to HIV-1. Sci Adv. 2018;4(2):e1701729.

  25. Ne E, Palstra RJ, Mahmoudi T. Transcription: Insights From the HIV-1 Promoter. Int Rev Cell Mol Biol. 2018;335:191-243.

  26. Marian CA, Stoszko M, Wang L, Leighty MW, de Crignis E, Maschinot CA, et al. Small Molecule Targeting of Specific BAF (mSWI/SNF) Complexes for HIV Latency Reversal. Cell Chem Biol. 2018;25(12):1443-55 e14.

  27. Abner E, Stoszko M, Zeng L, Chen HC, Izquierdo-Bouldstridge A, Konuma T, et al. A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs. J Virol. 2018;92(10).

  28. De Crignis E, Mahmoudi T. The Multifaceted Contributions of Chromatin to HIV-1 Integration, Transcription, and Latency. Int Rev Cell Mol Biol. 2017;328:197-252.

  29. Stoszko M, De Crignis E, Rokx C, Khalid MM, Lungu C, Palstra RJ, et al. Small Molecule Inhibitors of BAF; A Promising Family of Compounds in HIV-1 Latency Reversal. EBioMedicine. 2016;3:108-21.

  30. Rafati H, Parra M, Hakre S, Moshkin Y, Verdin E, Mahmoudi T. Correction: Repressive LTR Nucleosome Positioning by the BAF Complex Is Required for HIV Latency. PLoS Biol. 2015;13(11):e1002302.

  31. De Crignis E, Mahmoudi T. HIV eradication: combinatorial approaches to activate latent viruses. Viruses. 2014;6(11):4581-608.

  32. Mahmoudi T. The BAF complex and HIV latency. Transcription. 2012;3(4):171-6.

  33. Rafati H, Parra M, Hakre S, Moshkin Y, Verdin E, Mahmoudi T. Repressive LTR nucleosome positioning by the BAF complex is required for HIV latency. PLoS Biol. 2011;9(11):e1001206.

Publications: Text
bottom of page